Moving toward a cure: AstraZeneca’s commitment to the Lung Ambition Alliance

We have made incredible progress since AstraZeneca promised in 2014 to rebuild our oncology capabilities, with the goal of delivering 6 new medicines (NMEs) in the next 6 years. Five years later we’ve rebuilt our pipeline and launched 5 new and ground-breaking medicines in the continued pursuit of our goal; to one day eliminate cancer as a cause of death.

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide clinicians with medicines that can improve patient outcomes at every stage of the disease. But even the most promising treatments cannot stand alone in the fight against lung cancer. We recognise how much work we still have ahead of us. Barriers, delays, and disparities continue to limit lung cancer patients’ access to key diagnostic tests and treatments. As a result, the prognosis remains poor for lung cancer patients, with only one in five alive five years after they are diagnosed.1

We must act now to improve outcomes and survivability in lung cancer. Alone, we have the power to begin change, but together we can fundamentally alter the current mindset around the diagnosis, treatment and management of lung cancer. 

Rallying Behind a Common Cause
AstraZeneca is proud to join the International Association for the Study of Lung Cancer (IASLC), Guardant Health, and the Global Lung Cancer Coalition (GLCC), in forming the Lung Ambition Alliance, a new partnership with one bold goal. Our goal is ambitious, but, in our minds, attainable: to one day eliminate lung cancer as a cause of death.

 

 

The first step toward achieving our goal will be to double five-year survival for the disease by 2025.

To achieve this, we have identified three key areas of focus that span the patient journey:

  • Increasing lung cancer screening and early diagnosis: by raising awareness of the strong evidence for screening and addressing the barriers to early detection, with continued improvements to the ease and reliability of diagnostics technologies and contributions to a deeper understanding of disease progression2,3
  • Delivering innovative medicine: by enabling widespread paradigm shifts to earlier intervention when there is greater potential for a cure4,5
  • Improving quality care: by working with advocates and policymakers to deliver projects that address the challenges most urgent to patients, by improving coordination across the multidisciplinary team of healthcare professionals and by instilling the urgency to act

The Way Forward
With the creation of the Lung Ambition Alliance, we’re confident that together we can accelerate progress and bring meaningful change for patients by amplifying the complementary expertise of the partners and prioritising meaningful projects. Working with the medical community, the patients and their advocates, policy-makers and the administration, we will explore and overcome barriers and pursue an ambitious vision for the future together.

In this spirit, we are asking like-minded members of the medical, scientific, and advocacy communities to join us on the frontlines of lung cancer care. Please share your thoughts on the current state of lung cancer with us, or just visit us to learn more, at www.lungambitionalliance.org.

 

References

1. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed May 2019

2. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56

3. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409

4. NICE. The diagnosis and treatment of lung cancer (update). Available at

https://www.ncbi.nlm.nih.gov/books/NBK99021/pdf/Bookshelf_NBK99021.pdf. Accessed May 2019

5. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739

 

Veeva ID: Z4-18175

Date of Prep: 8 July 2019

Date of Expiry: 8 July 2021